Prior Authorization Required for Surgical/Interventional Codes

Prior authorization is required for surgical and interventional CPT/HCPCS codes related to facial reconstructive and reanimation procedures. Requests should include supporting clinical documentation demonstrating that selection criteria are met before services are scheduled.

• Prior authorization required for complex facial reconstructive/reanimation CPT/HCPCS codes
• Authorization must document that selection criteria (e.g., duration >12 months, functional deficit, lack of spontaneous recovery on EMG/ENoG) are met

Prior Authorization for Facial Reanimation

Prior authorization should be obtained for elective facial reanimation surgeries. Given limited high-quality randomized evidence, authorization is appropriate only when documentation supports medical necessity and conservative measures have been attempted or are not reasonable.

• Authorization expected for cross-facial nerve grafting, free functional muscle transfer, hypoglossal or masseteric nerve transfers, temporalis transposition, and related microvascular procedures
• Include rationale for surgery (cause of lesion, duration, prior treatments, functional deficits)

Authorization When Surgical Decompression Is Proposed

When facial nerve decompression is proposed, prior authorization must include objective evidence of severe paralysis and electrophysiologic testing supporting irrecoverable nerve degeneration. Documentation should justify surgical timing and approach.

• Required: House-Brackmann grade, duration since onset, and ENoG showing >90% degeneration or absent voluntary EMG when applicable
• Document proposed surgical approach (middle cranial fossa vs transmastoid), timing from symptom onset (e.g., ≤14 days vs >14 days), and expected benefits/risks

Prior Authorization Expectation for Selective Neurectomy

Selective neurectomy (SN) is considered a third-line, adjunctive surgical option for post-paralytic synkinesis and requires prior authorization only after failure or inadequate response to first-line therapies. Provide documentation of prior non-surgical management and rationale for SN.

• Authorization expected only after documented trials of botulinum toxin (chemo-denervation) and neuromuscular re‑training
• Document targeted symptoms (synkinesis type), prior Botox dosing/frequency and response, duration of non-surgical therapy, and planned extent of neurectomy/myectomy

Experimental/Investigational Exclusions Trigger Denial

Procedures and therapies designated as experimental or investigational will be denied. Prior authorization requests for these services should not be approved unless new, high-quality evidence justifies coverage.

• Services considered experimental/investigational: genetic analysis of facial muscle specimens, neural therapy, neuromuscular ultrasound (for diagnosis), blood thiol/disulphide testing, injection of platelet-rich plasma for this indication, photobiomodulation, acupuncture modalities listed
• Facial nerve decompression is listed among investigational treatments for Bell's palsy in portions of the policy — evaluate per indication and evidence; some decompression indications (selected trauma/time-limited) may be considered with documented criteria

Surgical Intervention Evidence Limited — Authorization Requires Careful Justification

Surgical interventions for Bell's palsy and other causes of facial paralysis have limited high-quality randomized evidence. Authorization decisions should reflect the uncertain benefit and the need for individualized clinical justification.

• Randomized evidence is very limited (small trials, low quality) and observational data guide much of current practice
• Authorization requires clear documentation of failure of conservative/medical therapy and objective measures supporting the anticipated benefit

Outcome Expectations for Alternative Motor Nerve Procedures

When alternative motor-nerve–based procedures (e.g., temporalis transposition, hypoglossal or accessory nerve neurotization) are proposed, prior authorization should set outcome expectations: these approaches may restore movement but often do not produce a spontaneous smile and outcomes differ from facial-nerve–based reinnervation.

• Document patient counseling about expected functional outcomes (e.g., temporalis transfers may produce voluntary but not spontaneous smile)
• Indicate reasons for selecting motor-nerve–based procedure (e.g., comorbidities, limited life expectancy, prior failed procedures)

Objective Electrophysiologic Confirmation Recommended Prior to Decompression

Objective electrophysiologic confirmation is recommended before authorizing facial nerve decompression. ENoG and EMG findings, when documented, should support the absence of spontaneous recovery potential.

• Include electroneuronography (ENoG) percent degeneration and EMG showing absent voluntary motor unit potentials where applicable
• Specify timing of tests relative to symptom onset and correlate with proposed surgical timing

Evidence Limitations May Affect Authorization

Evidence limitations (heterogeneity, small studies, observational designs) may affect authorization outcomes. Decisions should be individualized, and surgery generally considered third-line after noninvasive options have been exhausted.

• Authorization may be denied or limited when documentation does not address evidence gaps or fails to demonstrate prior appropriate therapies
• Consider multidisciplinary evaluation and second-opinion documentation when evidence is limited

Required Documentation for Facial Reconstructive Surgery

For facial reconstructive surgery (anastomosis, fascia slings, muscle transposition, cross-facial nerve grafting with microvascular muscle transfer), provide comprehensive operative planning and prior-treatment documentation to support medical necessity.

• Document duration of paralysis (>12 months for chronic procedures) and absence of meaningful spontaneous recovery
• Functional impairment described (mastication, speech, vision), prior EMG/ENoG results demonstrating lack of recovery potential, and rationale for chosen reconstructive technique
• Include prior non-operative therapies and outcomes, patient counseling regarding expected results and staged procedures

Required Clinical Documentation Elements

Authorization requests must include key clinical documentation elements to establish medical necessity and appropriate sequencing of care.

• Timing of treatment initiation (e.g., within 72 hours or 7 days for medical therapy where applicable) and time since onset of paralysis
• Diagnostic exclusion of alternate causes (e.g., zoster sine herpete) when relevant, and test results (ENoG, EMG, imaging)
• Functional status measures (House-Brackmann grade, Yanagihara or eFACE scores), and documentation of impact on activities (mastication, speech, vision)

Required Clinical Documentation for Surgical Reanimation

For surgical reanimation requests, include detailed clinical history and objective findings demonstrating appropriateness of the procedure and timing.

• Onset timing and etiology of lesion; prior treatments and responses (medical, Botox, re-training)
• Objective functional status (House-Brackmann grade), electrophysiologic testing results, and imaging when performed
• Rationale for selected reanimation technique (cross-facial grafting vs masseteric or hypoglossal transfers), staged treatment plan, and expected functional outcomes

Required Clinical Documentation for Decompression Consideration

For consideration of decompression surgery, include documentation of the degree and timing of paralysis plus electrophysiologic testing that supports the need for decompression versus continued medical management.

• House-Brackmann grade at presentation, timing since onset, and indication for decompression approach (MFD vs TMD)
• ENoG percent degeneration (e.g., >90%) or absent voluntary EMG within recommended windows, and imaging when performed
• If decompression is delayed, document reason and expected benefit given literature suggesting timing influences outcomes

Suggested Documentation for Selective Neurectomy (SN)

For selective neurectomy requests, suggest documentation elements that justify progression to surgery after conservative measures and that define the planned procedure and expected outcomes.

• Document prior use of botulinum toxin (Botox) with dates, doses, intervals, and clinical response
• Detail neuromuscular retraining efforts (duration, therapy goals, objective measures), synkinesis classification (type II/III), and failure or insufficiency of prior treatments
• Specify targeted branches for neurectomy/myectomy, anticipated reduction in Botox need, and plans for adjunctive reanimation if applicable

Conservative Management Expected Before Surgery

Conservative management is expected before considering elective facial surgery. There is no single mandated step-therapy algorithm, but non-surgical options should be trialed and documented prior to authorization for invasive procedures.

• First-line conservative measures include facial exercises, massage, neuromuscular re‑training, and appropriate medical therapy (see medical sequencing)
• Document trials of conservative care and objective responses; surgical referral without reasonable conservative attempts should be justified

Medical Therapy Sequencing

Medical therapy sequencing: early systemic corticosteroids are supported for new-onset Bell's palsy; antivirals alone lack clear benefit but may be considered in combination with corticosteroids in selected severe cases.

• Recommend early prednisolone (within 72 hours) for Bell's palsy as first-line medical therapy
• Antivirals (acyclovir/valacyclovir) do not add clear benefit alone; combination with corticosteroids may offer incremental benefit in some analyses particularly for severe palsy

Step Therapy: Medications for Bell's Palsy

Step therapy for medications in Bell's palsy: systemic corticosteroids are the initial therapy; antivirals may be added in severe presentations but are not routinely required.

• Initial therapy: systemic corticosteroids (prednisone/prednisolone) within recommended window
• Reserve adding antiviral therapy for severe cases or based on treating clinician judgment and documented rationale

Triage of Synkinesis Therapies

Triage of therapies for post-paralytic synkinesis should prioritize non-surgical options (chemo-denervation and neuromuscular retraining). Surgical options, including selective neurectomy, are third-line and require documentation of prior therapies and limited response.

• First-line: botulinum toxin injections (Botox) and structured neuromuscular re‑training
• Consider SN, myectomy, or reanimation procedures only after adequate trials of first-line therapies with objective documentation of persistent disabling synkinesis

Step Therapy Pathway

Step therapy pathway for synkinesis: require documented progression through first-line non-surgical interventions before authorizing surgical interventions; selective neurectomy should be reserved for refractory cases.

• Step 1: Chemo-denervation with botulinum toxin and documented response assessment
• Step 2: Neuromuscular retraining for an adequate course with objective measures (eFACE, FaCE, House-Brackmann)
• Step 3: Consider selective neurectomy, myectomy, or reanimation only if Steps 1–2 fail or are contraindicated, with detailed justification